Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Apollo_CSM-102
|
| gptkbp:activities |
facilitates cellular uptake
|
| gptkbp:application |
gptkb:physicist
vaccine adjuvant |
| gptkbp:associated_with |
COVID-19 vaccines
|
| gptkbp:category |
lipid-based delivery systems
|
| gptkbp:class |
lipid
|
| gptkbp:clinical_trial |
ongoing
under study potential for vaccines |
| gptkbp:collaborations |
various pharmaceutical companies
international collaborations |
| gptkbp:community |
actively researched
|
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:developed_by |
Moderna, Inc.
|
| gptkbp:dissolved |
insoluble in water
soluble in ethanol soluble in chloroform |
| gptkbp:environmental_impact |
not assessed
|
| gptkbp:field_of_study |
gptkb:Company
|
| gptkbp:financial_performance |
stable under proper storage conditions
|
| gptkbp:first_described_by |
gptkb:2020
|
| gptkbp:formulation |
part of lipid formulations
|
| gptkbp:future_plans |
focused on safety and efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
SM-102
|
| gptkbp:impact |
immune response
|
| gptkbp:ingredients |
C22 H29 N3 O5 S
|
| gptkbp:invention |
patented
Moderna, Inc. protected by patents |
| gptkbp:is_a_route_for |
multi-step synthesis
|
| gptkbp:is_analyzed_in |
HPLC
|
| gptkbp:is_characterized_by |
NMR
|
| gptkbp:is_used_for |
delivery of nucleotides
|
| gptkbp:market |
not commercially available
|
| gptkbp:produced_by |
laboratory scale
|
| gptkbp:project |
preclinical
|
| gptkbp:publishes |
numerous scientific articles
|
| gptkbp:receives_funding_from |
government and private grants
|
| gptkbp:regulatory_compliance |
under investigation
not yet approved |
| gptkbp:related_to |
lipid nanoparticles
|
| gptkbp:research_areas |
various universities
|
| gptkbp:safety_features |
subject to regulations
limited data available not fully established potential toxicity |
| gptkbp:social_structure |
contains a thiol group
|
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
eukaryotic cells
|
| gptkbp:type_of |
1866327-69-4
|
| gptkbp:used_in |
m RNA vaccine development
|
| gptkbp:uses |
experimental research
|
| gptkbp:weight |
453.55 g/mol
|